Rafael Holdings Inc. is dedicated to the development of innovative cancer and immune therapies, positioning itself as a significant investor in clinical-stage oncology companies such as Cornerstone Pharmaceuticals, Inc. and LipoMedix Pharmaceuticals Ltd. The company is actively seeking to expand its portfolio by investing in, acquiring, or in-licensing additional therapeutic assets that address critical unmet medical needs in oncology. With a focus on novel cancer therapeutics, Rafael Holdings aims to enhance and prolong the lives of patients through its controlled portfolio of companies, which includes multiple ongoing clinical programs, including two Phase 3 trials.

In addition to its investment strategy, Rafael Holdings emphasizes a robust compliance and ethics framework to navigate the complex regulatory landscape of the pharmaceutical industry. The company is committed to developing and implementing comprehensive compliance programs that adhere to U.S. laws and industry standards, including FDA regulations and anti-kickback statutes. This commitment extends to fostering a culture of compliance and business ethics, ensuring that all interactions with healthcare professionals and patients are conducted transparently and responsibly. By prioritizing compliance, Rafael Holdings aims to support the successful development and commercialization of its pharmaceutical products while minimizing risks associated with healthcare fraud and abuse.

United States

Rafael Holdings, Inc. owns commercial real estate assets and interests in pre-clinical and clinical stage pharmaceutical companies. The company operates in two segments, Pharmaceuticals and Real Estate. It engages in the leasing of a commercial office building, as well as an associated 800-car public garage; and development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.

Cancer

Immune System Diseases

Rafael Holdings Inc

Blood cancer

Leukemia

Lymphoma

CPI-613 is a lipoate &nbsp;derivative synthesized to be catalytically inert but to potentially &nbsp;mimic lipoate catalytic intermediates. The drug is in phase II of &nbsp;clinical trials for the treatment of Myelodysplastic syndromes; &nbsp;Pancreatic cancer; Small cell lung cancer; Solid tumors; Bile duct &nbsp;cancer; Acute Myeloid leukemia. The mechanism of CPI-613 action can be &nbsp;explained by (I) inhibition of tumor cell pyruvate dehydrogenase complex &nbsp;(PDC) through activation of pyruvate dehydrogenase kinases leading to &nbsp;inactivating phosphorylation of the E1alpha-subunit of PDC; and (II) &nbsp;inhibition of alpha-ketoglutarate dehydrogenase.
<a href="https://drugs.ncats.io/drug/E76113IR49">Source</a>

Rafael Holdings Inc

Company Details